Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Establishment and Characterization of Novel Patient-Derived Cancer Model
share announcement

Establishment and Characterization of Novel Patient-Derived Cancer Model

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 31 July 2025 | Viewed by 402

Special Issue Editors

Dr. Yuki Yoshimatsu

E-Mail Website
Guest Editor
Medical Seeds Discovery Project, Tochigi Cancer Center Research Institute, 4-9-13 Yohnan, Utsunomiya, Tochigi 320-0834, Japan
Interests: patient-derived cancer model; rare cancer research; sarcoma; expanded indication; biobank; viral carcinogenesis; transcriptomics; exosome/miRNA; tissue culture; primary culture
Special Issues, Collections and Topics in MDPI journals
Dr. Tadashi Kondo

E-Mail Website
Guest Editor
Division of Pharmacoproteomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Interests: rare cancer research; sarcoma; proteogenomics; applications of patient-derived cancer model
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Patient-derived cancer models are transformative tools that have advanced our understanding of cancer biology and catalyzed breakthroughs in personalized medicine. These models support functional investigations of novel genes and proteins, provide platforms for the high-throughput screening of anti-cancer agents, and illuminate the molecular underpinnings of tumor progression. Despite these achievements, significant gaps remain, particularly for rare and underrepresented cancer types, underscoring the need to expand and share these resources within the research community.

This Special Issue, titled "Establishment and Characterization of Novel Patient-Derived Cancer Models", aims to spotlight the latest advancements in this critical area. We welcome original research articles and reviews addressing the development and characterization of novel cancer models derived from patient samples, as well as innovative methodologies for model establishment and applications in functional genomics and drug discovery. Submissions may also explore the integration of patient-derived models with emerging technologies to tackle unresolved questions in cancer research. Moreover, novel cancer models that advance our understanding of etiology and disease progression, as well as support precision medicine, are valuable topics of discussion across various cancer types. By gathering these cutting-edge contributions, we seek to foster collaboration and knowledge exchange, ultimately broadening the utility of patient-derived models in both basic and translational cancer research. We look forward to your submissions and insights.

Dr. Yuki Yoshimatsu
Dr. Tadashi Kondo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • patient-derived cancer model
  • primary tissue culture
  • cell line
  • spheroid
  • organoid
  • xenograft
  • PDX
  • organ-on-a-chip
  • comparative oncology
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 17805 KiB  
Article
Accumulation of Small-Size, Highly Dispersive Mesoporous Silica Nanoparticles in a Tumor in Both Chorioallantoic Membrane and Mouse Models
by Aoi Komatsu, Yuya Higashi, Cong-Kai Lin, Yi-Ping Chen, Si-Han Wu, Minoru Suzuki, Kotaro Matsumoto and Fuyuhiko Tamanoi
Cells 2025, 14(10), 734; https://doi.org/10.3390/cells14100734 - 17 May 2025
Viewed by 218
Abstract
(1) Background: The chorioallantoic membrane (CAM) model has the potential to contribute to the development of personalized medicine based on individual cancer patients. We previously established the CAM model using patient-derived CIC-DUX4 sarcoma cells. We also used the CAM model for characterization and [...] Read more.
(1) Background: The chorioallantoic membrane (CAM) model has the potential to contribute to the development of personalized medicine based on individual cancer patients. We previously established the CAM model using patient-derived CIC-DUX4 sarcoma cells. We also used the CAM model for characterization and a comparison with the mouse model by examining the tumor accumulation of small-size, highly dispersive mesoporous silica nanoparticles (MSNs). (2) Method: In this study, we transplanted a variety of cancer cell lines, including patient-derived osteosarcoma (OS) and extraskeletal osteosarcoma (ESOS) cells. Patient-derived OS, ESOS and other cell lines were transplanted onto CAMs. The proliferation of cancer cells within CAM tumors was confirmed using H&E staining. For the comparison of the CAM and mouse models, rhodamine B-labeled MSNs were administered intravenously to CAMs and to xenograft mice. Tumor accumulation was evaluated by examining fluorescence and by confocal microscopy. The biodistribution of MSNs was examined by measuring the Si content by ICP. (3) Results: H&E staining demonstrated the proliferation of cancer cells of OS, ESOS and others on CAMs. While growth patterns and morphologies varied among different cancer types, H&E staining confirmed the establishment of tumors. As for the tumor accumulation, both the CAM and mouse models showed that MSNs were selectively accumulated in the tumors in both the CAM and mouse models. (4) Conclusions: We have expanded the range of CAM models by using a variety of cancer cells, including patient-derived cell lines. We also report that the small-size, highly dispersive MSNs exhibit excellent tumor accumulation in both the CAM and mouse models. These results point to the usefulness of the CAM model for patient-derived cancer cells as well as for evaluating drug carriers for tumor targeting. Full article
(This article belongs to the Special Issue Establishment and Characterization of Novel Patient-Derived Cancer Model)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop